Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Kosuke Takemura, Daniel Yick Chin Heng, Naveen S. Basappa et al.|Journal of Clinical Oncology|2025Cited by 2
Clinical outcomes of patients with primary refractory metastatic renal cell carcinoma receiving second-line (2L) therapies: An International Metastatic Database Consortium (IMDC) study.Marc Eid, Daniel Yick Chin Heng, Karl Semaan et al.|Journal of Clinical Oncology|2025Cited by 0
Low versus low-intermediate risk metastatic renal cell carcinoma (mRCC): Contemporary data from the International mRCC Database Consortium (IMDC).Razane El Hajj Chehade, Toni K. Choueiri, Wanling Xie et al.|Journal of Clinical Oncology|2025Cited by 0
Real-world efficacy of nivolumab plus cabozantinib in metastatic renal cell carcinoma (mRCC) using the IMDC.Martín Zarbá, Daniel Yick Chin Heng, David Maj et al.|Journal of Clinical Oncology|2026Cited by 0
Efficacy and safety of belzutifan in patients with metastatic clear cell renal cell carcinoma (mccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Chris Labaki, Rana R. McKay, Caiwei Zhong et al.|Journal of Clinical Oncology|2026Cited by 0